Halted trials causes Oxford Biomedica plunge
Shares in Oxford BioMedica plunged 28 per cent yesterday as the biopharmaceutical company put some of its trials on hold after discovering "potential impurities" in one of its raw materials.
The gene-based pharmaceuticals company said the paused trials were for its RetinoStat macular degeneration eye disease treatment, its StarGen medicine for Stargardt eye disease and UshStat for Usher syndrome, the most common form of deaf-blindness.
The company said that a new, highly-sensitive test method it has recently introduced had detected the impurities at very low concentrations. The trials were on hold "as a precautionary measure," Oxford BioMedica said, "while the company investigates the recent detection of very low concentrations of potential impurities derived from a widely used third party raw material."
The pharmaceuticals company added: "No safety concerns relating to any of the aforementioned products have been identified in any pre-clinical and clinical data generated to date and there is no reason to believe that the favourable safety profile of these products will be affected."
Oxford BioMedica said it was "working very closely" with pharmaceutical regulatory authorities to complete its investigations, adding: "the company is committed to resuming the clinical trials as soon as possible and will continue to keep the market informed as appropriate."
Shares in Oxford BioMedica fell 0.65p to 1.65p.
- 1 Belgium fan Axelle Despiegelaere lands L'Oreal campaign after World Cup viral photo
- 2 Why I'm on the brink of burning my Israeli passport
- 3 Israel-Gaza conflict: ‘Sderot cinema’ image shows Israelis with popcorn and chairs 'cheering as missiles strike Palestinian targets'
- 4 Blackest is the new black: Scientists have developed a material so dark that you can't see it...
- 5 Iraq crisis: How Saudi Arabia helped Isis take over the north of the country
Scottish independence: Scots of Corby take matters into their own hands in mock referendum - and deliver overwhelming verdict
Protesters fight to save Arturo, the polar bear sweltering in baking hot zoo
Fry ‘criticises Operation Yewtree in dinner party rant’ calling for tougher laws to deter false sex abuse allegations
Supermoon 2014 in pictures: Moon appeared bigger and brighter at the weekend
Saharan remains may be evidence of first race war, 13,000 years ago
Sustained immigration has not harmed Britons' employment, say government advisers
War is war: Why I stand with Israel
Even when it brutalises one of its own teenage citizens, America is helpless against Israel
Socialist Worker called to apologise over ‘vile’ article saying Eton schoolboy Horatio Chapple's death is ‘reason to save the polar bears’
Emergency data law: David Cameron plots to bring back snoopers’ charter
NUT strike: David Cameron announces crackdown on strike action ahead of mass industrial action
iJobs Money & Business
£35000 - £40000 per annum + Benefits: Ashdown Group: HR Advisor - 6 Months Fix...
£70000 per annum: Harrington Starr: Information Security Manager (ISO 27001, A...
£75000 - £85000 per annum + ex bens: Deerfoot IT Resources Limited: Biztalk Te...
£60000 per annum: Harrington Starr: Trade Desk Specialist (FIX, Linux, Windows...